Nice DD.
Posted by: gophilipgo
In reply to: None Date:4/7/2013 9:27:00 PM
Post #1370 of 1373
I emailed TZYM investor relations this past week and asked a couple of questions. Here are the responses I got. Pretty telling, as far as I'm concerned. Just a matter of time. Pay particular attention to the answer regarding monthly cash burn.
From: xxxxxxxxxxxx
Sent: Tuesday, April 02, 2013 1:25 PM
To: Susan Sharpe
Subject: Investor Question
Hi. I have xxxxxxxxxxxxxxx shares of Tranzyme. I am wondering...is the company still working with Stifel in regards to a sale, and if so, is there any sort of timetable regarding resolution? Any info would be appreciated.
Thanks,
Phil
From: ssharpe@tranzyme.com
To: xxxxxxxxxxxxxx
Subject: RE: Investor Question
Date: Tue, 2 Apr 2013 17:38:21 +0000
Dear Mr. xxxxxxxxxx, thank you for your email. Yes, the company is still working with Stifel to review and evaluate various strategic alternatives available to Tranzyme; however, there is no set timetable for the process.
Thank you for your interest in Tranzyme.
Best regards,
Susan Sharpe
From: xxxxxxxxxxxxxxxxx
Sent: Friday, April 05, 2013 11:21 AM
To: Susan Sharpe
Subject: RE: Investor Question
Thank you, Susan. One last question... The 10K didn't report the anticipated monthly cash burn rate for 2013, as they typically do. Do you happen to have this information?
Phil
From: ssharpe@tranzyme.com
To: xxxxxxxxxxxxxxxxxxxx
Subject: RE: Investor Question
Date: Sun, 7 Apr 2013 17:25:12 +0000
Unfortunately, I don’t have that information. I can tell you that all clinical trial and development activities have been suspended and expense management is a high priority while we evaluate alternatives.
Best regards,
Susan Sharpe
Replies(1) | Previous | Next
